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Abstract
Background: CancerMath is a set of web-based prognostic tools which predict nodal status and survival up to
15 years after diagnosis of breast cancer. This study validated its performance in a Southeast Asian setting.
Methods: Using Singapore Malaysia Hospital-Based Breast Cancer Registry, clinical information was retrieved from
7064 stage I to III breast cancer patients who were diagnosed between 1990 and 2011 and underwent surgery.
Predicted and observed probabilities of positive nodes and survival were compared for each subgroup. Calibration
was assessed by plotting observed value against predicted value for each decile of the predicted value.
Discrimination was evaluated by area under a receiver operating characteristic curve (AUC) with 95 % confidence
interval (CI).
Results: The median predicted probability of positive lymph nodes is 40.6 % which was lower than the observed
43.6 % (95 % CI, 42.5 %–44.8 %). The calibration plot showed underestimation for most of the groups. The AUC was
0.71 (95 % CI, 0.70–0.72). Cancermath predicted and observed overall survival probabilities were 87.3 % vs 83.4 % at
5 years after diagnosis and 75.3 % vs 70.4 % at 10 years after diagnosis. The difference was smaller for patients from
Singapore, patients diagnosed more recently and patients with favorable tumor characteristics. Calibration plot also
illustrated overprediction of survival for patients with poor prognosis. The AUC for 5-year and 10-year overall
survival was 0.77 (95 % CI: 0.75–0.79) and 0.74 (95 % CI: 0.71–0.76).
Conclusions: The discrimination and calibration of CancerMath were modest. The results suggest that clinical
application of CancerMath should be limited to patients with better prognostic profile.
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Background
Adjuvant chemotherapy and hormone therapy improve
long-term survival and reduce the risk of recurrence in
early breast cancer patients [1–3]. However, the benefit
varies greatly from patient to patient due to biologic het-
erogeneity of the disease and differences in response to
treatment [4, 5]. Risk of adverse effects and high cost of
adjuvant therapy also make it challenging for oncologists
to choose the most appropriate treatment. Therefore,
several clinical tools have been developed to predict
prognosis and survival benefit from treatment, using
clinicopathological features, genetic profiles, and novel
biomarkers [6].
The Nottingham Prognostic Index was the first prog-
nostic model introduced for breast cancer patients in
1982. It includes only tumor grade, size, and nodal status
for prediction of disease-free survival [7, 8]. The widely
used Adjuvant! Online (www.adjuvantonline.com) calcu-
lates 10-year overall survival and disease-free survival of
patients with non-metastatic breast cancer, based on
patient’s age, tumor size, grade, estrogen-receptor (ER)
status, nodal status, and co-morbidities. It also quantita-
tively predicts the absolute gain from adjuvant therapy
[9]. Although it is recommended by the National Insti-
tute for Health and Clinical Excellence and widely used
by oncologists [10–13], several validation studies have
suggested that Adjuvant! Online is suboptimal in women
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younger than 40 years and older than 75 years [14, 15].
The model was recently validated in Malaysia, Korea,
and Taiwan, where it was shown to substantially over-
estimate actual survival [16–18]. CancerMath (http://
www.lifemath.net/cancer/) is the latest web-based prog-
nostic tool, which takes human epidermal growth factor
receptor 2 (HER2) status into account [19]. It was estab-
lished based on the binary biological model of cancer
metastasis and the parameters were derived from the
Surveillance, Epidemiology and End-Result (SEER) regis-
try in the United States [20]. CancerMath provides infor-
mation on overall survival, conditional survival (the
likelihood of surviving given being alive after a certain
number of years) and benefit of systemic treatment for
each of the first 15 years after diagnosis. This model also
estimates probability of positive lymph nodes and nipple
involvement. Validation study has shown comparable re-
sults between CancerMath and Adjuvant! Online [19].
However this new tool has not been validated outside
the United States. Given the differences in underlying
distribution of prognostic factors and life expectancy be-
tween Asia and the United States [21–23], direct appli-
cation without any correction may not generate reliable
prediction. The aim of the study is to validate this model
in the Singapore Malaysia Hospital-Based Breast Cancer
Registry, demonstrating its predictive performance for
different subgroups and determining its calibration and
discrimination.
Methods
Women diagnosed with pathological stage I to III breast
cancer according to American Joint Committee on
Cancer Staging Manual sixth edition, who underwent
surgery, were identified from the Singapore Malaysia
Hospital-Based Breast Cancer Registry, which combined
databases from three public tertiary hospitals. The breast
cancer registry at National University Hospital (NUH) in
Singapore collects information on breast cancer patients
diagnosed since 1990. The Tan Tock Seng Hospital
(TTSH) registry registers patients diagnosed from 2001
onwards. The University Malaya Medical Centre
(UMMC), located in Kuala Lumpur, Malaysia, has
Table 1 Observed number of patients with positive lymph









Overall 6807 2970 (43.6 %) 40.6 %
Ethnicity
Chinese 5029 2062 (41.0 %) 39.2 %
Malay 963 511 (53.1 %) 46.0 %
Indian 651 312 (47.9 %) 44.7 %
Other 164 85 (51.8 %) 39.5 %
Country
Malaysia 3274 1460 (44.6 %) 43.0 %
Singapore 3533 1510 (42.7 %) 38.5 %
Period of diagnosis
1990–1994 124 58 (46.8 %) 52.0 %
1995–1999 547 258 (47.2 %) 41.9 %
2000–2003 1744 755 (43.3 %) 41.4 %
2004–2007 2129 964 (45.3 %) 41.2 %
2008–2011 2263 935 (41.3 %) 38.9 %
Age at diagnosis
0–39 670 310 (46.3 %) 47.1 %
40–49 2039 910 (44.6 %) 42.9 %
50–59 2145 934 (43.5 %) 41.4 %
60–69 1301 546 (42.0 %) 36.7 %
70+ 652 270 (41.4 %) 34.3 %
Tumor size (mm)
0–20 2926 822 (28.1 %) 26.4 %
21–50 3247 1678 (51.7 %) 49.3 %
51+ 634 470 (74.1 %) 79.2 %
ER status
Negative 2316 1037 (44.8 %) 43.5 %
Positive 4254 1854 (43.6 %) 38.5 %
Unknown 237 79 (33.3 %) 44.5 %
PR status
Negative 2656 1195 (45.0 %) 42.1 %
Positive 3507 1511 (43.1 %) 38.5 %
Unknown 644 264 (41.0 %) 44.2 %
Her2 status
Negative 2872 1197 (41.7 %) 39.2 %
Equivocal 429 182 (42.4 %) 39.2 %
Positive 1315 662 (50.3 %) 45.0 %
Unknown 2191 929 (42.4 %) 39.6 %
Histology
Ductal 5945 2681 (45.1 %) 41.5 %
Lobular 287 150 (52.3 %) 37.9 %
Mucinous 219 34 (15.5 %) 10.7 %
Table 1 Observed number of patients with positive lymph
nodes and predicted probability of positive nodes (Continued)
Others 352 102 (29.0 %) 35.8 %
Unknown 4 3 (75.0 %) 25.1 %
Grade
1 849 204 (24.0 %) 21.8 %
2 2836 1278 (45.1 %) 40.6 %
3 2463 1275 (51.8 %) 46.4 %
Unknown 659 213 (32.3 %) 35.9 %
Miao et al. BMC Cancer  (2016) 16:820 Page 2 of 12












(%) (95 % CI)
Overall 4517 752 667 1.13(1.05,1.21) 83.4 (0.006) 87.3 3.9 (2.7,5.1)
Ethnicity
Chinese 3340 488 478 1.02(0.93,1.12) 85.4 (0.006) 88.0 2.6 (1.4,3.8)
Malay 654 143 104 1.38(1.16,1.62) 78.1 (0.016) 85.8 7.7 (4.6,10.8)
Indian 430 109 71 1.54(1.26,1.85) 74.7 (0.021) 85.1 10.4 (6.3,14.5)
Other 93 12 14 0.86(0.44,1.50) 87.1 (0.035) 87.3 0.2 (−6.7,7.1)
Country
Malaysia 2143 423 331 1.28(1.16,1.41) 80.3 (0.009) 86.1 5.8(4.0,7.6)
Singapore 2374 329 336 0.98(0.88,1.09) 86.1 (0.007) 88.6 2.5(1.1,3.9)
Period of diagnosis
1990–1994 140 41 22 1.86(1.34,2.53) 70.7 (0.038) 85.9 15.2 (7.8,22.6)
1995–1999 564 116 75 1.55(1.28,1.86) 79.8 (0.017) 87.9 8.1 (4.8,11.4)
2000–2003 1800 279 261 1.07(0.95,1.20) 84.5 (0.009) 87.8 3.3 (1.5,5.1)
2004–2007 2013 316 309 1.02(0.91,1.14) 84.3 (0.008) 87.2 2.9 (1.3,4.5)
Age at diagnosis
0–39 493 101 64 1.58(1.29,1.92) 79.5 (0.018) 88.8 9.3(5.8,12.8)
40–49 1430 172 163 1.06(0.90,1.23) 88.0 (0.009) 90.6 2.6(0.8,4.4)
50–59 1412 224 194 1.15(1.01,1.32) 84.1 (0.010) 88.2 4.1(2.1,6.1)
60–69 776 126 130 0.97(0.81,1.15) 83.8 (0.013) 85.1 1.3(−1.2,3.8)
70+ 406 129 117 1.10(0.92,1.31) 68.2 (0.023) 73.9 5.7 (1.2,10.2)
Tumor size (mm)
0–20 1889 151 173 0.87(0.74,1.02) 92.0 (0.006) 92.9 0.9(−0.3,2.1)
21–50 2180 438 374 1.17(1.06,1.29) 79.9 (0.009) 84.8 4.9 (3.1,6.7)
51+ 448 163 121 1.35(1.15,1.57) 63.6 (0.023) 73.6 10.0(5.5,14.5)
Number of positive nodes
0 2408 196 238 0.82(0.71,0.95) 91.9 (0.006) 91.7 −0.2(−1.4,1.0)
1–3 1068 195 165 1.18(1.02,1.36) 81.7 (0.012) 85.9 4.2(1.8,6.6)
4–9 533 159 122 1.30(1.11,1.52) 70.2 (0.020) 78.0 7.8(3.9,11.7)
10+ 354 170 116 1.47(1.25,1.70) 52.0 (0.027) 67.4 15.4(10.1,20.7)
Unknown 154 32 27 1.19(0.81,1.67) 79.2 (0.033) 86.6 7.4(0.9,13.9)
ER status
Negative 1595 392 268 1.46(1.32,1.61) 75.4 (0.011) 85.2 9.8 (7.6,12.0)
Positive 2668 309 367 0.84(0.75,0.94) 88.4 (0.006) 88.8 0.4(−0.8,1.6)
Unknown 254 51 33 1.55(1.15,2.03) 79.9 (0.025) 88.6 8.7(3.8,13.6)
PR status
Negative 1674 382 289 1.32(1.19,1.46) 77.2 (0.010) 84.8 7.6(5.6,9.6)
Positive 2174 241 285 0.85(0.74,0.96) 88.9 (0.007) 89.5 0.6(−0.8,2.0)
Unknown 669 129 93 1.39(1.16,1.65) 80.7 (0.015) 87.4 6.7 (3.8,9.6)
Her2 status
Negative 1483 208 210 0.99(0.86,1.13) 86.0 (0.009) 88.0 2.0(0.2,3.8)
Equivocal 118 19 19 1.00(0.60,1.56) 83.9 (0.034) 87.4 3.5(−3.2,10.2)
Positive 790 172 147 1.17(1.00,1.36) 78.2 (0.015) 83.0 4.8(1.9,7.7)
Unknown 2126 353 292 1.21(1.09,1.34) 83.4 (0.008) 88.7 5.3(3.7,6.9)
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prospectively collected data on breast cancer patients di-
agnosed since 1993 [24]. No consent was needed and eth-
ics approval was obtained from Domain Specific Review
Board under National Healthcare Group in Singapore and
Medical Ethics Committee under UMMC. The consoli-
dated registry included information on ethnicity, age and
date of diagnosis, histologically determined tumor size,
number of positive lymph nodes, ER and progesterone re-
ceptor (PR) status (positive defined as 1 % or more posi-
tively stained tumor cells at NUH or 10 % or more
positively stained tumor cells at TTSH and UMMC, nega-
tive, or unknown), HER2 status based on fluorescence in
situ hybridization (FISH) or immunohistochemistry (IHC)
if FISH was not performed (positive defined as FISH posi-
tive or IHC score of 3+, negative defined as FISH negative
or IHC scored of 0 or 1+, equivocal defined as IHC score
of 2+, or unknown), histological type (ductal, lobular, mu-
cinous, others, or unknown), grade (1, 2, 3, or unknown),
type of surgery (no surgery, mastectomy, breast conserv-
ing surgery, or unknown), chemotherapy (yes, no or un-
known), hormone therapy (yes, no, or unknown), and
radiotherapy (yes, no, or unknown). Detailed chemothera-
peutic treatment regimens were only available for UMMC
patients. For chemotherapy, cyclophosphamide, metho-
trexate and fluorouracil (CMF) was categorized as first
generation regimen and fluorouracil, epirubicin and cyclo-
phosphamide (FEC), and doxorubicin and cyclophospha-
mide (AC) followed by paclitaxel were second generation.
Docetaxel, doxorubicin and cyclophosphamide (TAC),
and FEC followed by docetaxel were categorized as third
generation. Hormone therapy was categorized into five
groups: tamoxifen, aromatase inhibitors (AI), tamoxifen
followed by AI, ovarian ablation, and ovarian ablation plus
tamoxifen. Vital status was obtained from the hospitals'
medical records and ascertained by linkage to death regis-
tries in both countries. Patients diagnosed until 31st De-
cember 2011 were followed up from date of diagnosis until
date of death or date of last fellow-up, whichever came first.
Date of last follow-up was 1st March 2013 for UMMC, 31st
July 2013 for NUH, and 1st October 2012 for TTSH. Male
patients, patients with unknown age at diagnosis and tumor
size were excluded from this analysis as these two were
essential predictors for all four CancerMath calculators.
Javascript codes of all four CancerMath calculators which
contained predetermined parameters and mathematical
equations were exported on 9th Nov 2013 from its website
by selecting “view- > source” in the browser menu. The
script was then transcribed into R script to allow calcula-
tion for a group of patients. For nodal status calculator, pa-
tient’s age, tumor size, ER and PR status, histological type,
and grade were used by the program to calculate probabil-
ity of positive nodes for each patient. Overall mortality risk
at each year up to 15 year after diagnoses was predicted by
outcome calculator, based on age, tumor size, number of
positive nodes, grade, histological type, ER, PR, and HER2
status. Effect of hormone and chemotherapeutic regimen
on overall mortality was further adjusted by the therapy cal-
culator and number of years since diagnosis were consid-
ered in the conditional survival calculator. Results from R
script and website were crosschecked with a random subset
of 20 patients to verify the accuracy of R script. Histological
type recorded as others was re-categorized as unknown. If
HER2 status was equivocal based on IHC and FISH was
not performed, HER2 status was treated as unknown. Evi-
dence of recurrence was set as unknown for conditional
survival calculation.
In total, 7064 female breast cancer patients were in-
cluded. Only cases with known nodal status (N = 6807)
were included for validation of nodal status calculator
and their individual probability of positive lymph nodes
was calculated. For outcome calculator, two separate
subsets of patients with minimum 5-year follow up
(UMMC and NUH patients diagnosed in 2007 and earl-
ier and TTSH patient diagnosed in 2006 and earlier,
N = 4517) and patients with 10-year follow-up UMMC
and NUH cases diagnosed in 2002 and earlier, N = 1649)
Table 2 Observed and predicted 5-year overall survival from outcome calculator, stratified by patients’ characteristics (Continued)
Histology
Ductal 3951 696 597 1.17(1.08,1.26) 82.4 (0.006) 87.0 4.6 (3.4,5.8)
Lobular 180 17 26 0.65(0.38,1.05) 90.6 (0.022) 87.5 −3.1(−7.4,1.2)
Mucinous 156 10 14 0.71(0.34,1.31) 93.6 (0.020) 94.7 1.1(−2.8,5.0)
Others 227 29 30 0.97(0.65,1.39) 87.2 (0.022) 89.5 2.3(−2.0,6.6)
Unknown 3 0 0 - 100 86.8 −13.2
Grade
1 552 20 44 0.45(0.28,0.70) 96.4 (0.008) 94.7 −1.7(−3.3,–0.1)
2 1882 261 265 0.98(0.87,1.11) 86.1 (0.008) 88.2 2.1(0.5,3.7)
3 1591 402 288 1.40(1.26,1.54) 74.7 (0.011) 84.3 9.6(7.4,11.8)
Unknown 492 69 70 0.99(0.77,1.25) 86.0 (0.016) 87.4 1.4(−1.7,4.5)
Numbers marked in bold indicate statistically significant difference at the 95% confidence level
Miao et al. BMC Cancer  (2016) 16:820 Page 4 of 12












(%) (95 % CI)
Overall 1649 488 454 1.07(0.98,1.17) 70.4 (0.011) 75.3 4.9 (2.7,7.1)
Ethnicity
Chinese 1201 318 318 1.00(0.89,1.12) 73.5 (0.013) 76.8 3.3 (0.8,5.8)
Malay 251 100 74 1.35(1.10,1.64) 60.2 (0.031) 72.3 12.1(6.0,18.2)
Indian 174 64 55 1.16(0.90,1.49) 63.2 (0.037) 69.9 6.7 (−0.6,14.0)
Other 23 6 7 0.86(0.31,1.87) 73.9 (0.092) 77.1 3.2 (−14.8,21.2)
Country
Malaysia 983 341 284 1.20(1.08,1.34) 65.3 (0.015) 73.3 8.0 (5.1,10.9)
Singapore 666 147 170 0.86(0.73,1.02) 77.9 (0.016) 77.9 0.0 (−3.1,3.1)
Period of diagnosis
1990–1994 140 56 42 1.33(1.01,1.73) 60.0 (0.041) 72.5 12.5(4.5,20.5)
1995–1999 564 187 148 1.26(1.09,1.46) 66.8 (0.020) 76.0 9.2 (5.3,13.1)
2000–2002 945 245 264 0.93(0.82,1.05) 74.1 (0.014) 75.9 1.8 (−0.9,4.5)
Age at diagnosis
0–39 232 82 58 1.41(1.12,1.75) 64.7 (0.031) 77.3 12.6 (6.5,18.7)
40–49 576 137 130 1.05(0.88,1.25) 76.2 (0.018) 80.2 4.0 (0.5,7.5)
50–59 493 141 129 1.09(0.92,1.29) 71.4 (0.020) 76.4 5.0 (1.1,8.9)
60–69 254 78 86 0.91(0.72,1.13) 69.3 (0.029) 68.4 −0.9 (−6.6,4.8)
70+ 94 50 50 1.00(0.74,1.32) 46.8 (0.051) 50.1 3.3 (−6.7,13.3)
Tumor size (mm)
0–20 653 118 109 1.08(0.90,1.30) 81.9 (0.015) 86.8 4.9 (2.0,7.8)
21–50 831 283 262 1.08(0.96,1.21) 65.9 (0.016) 70.6 4.7 (1.6,7.8)
51+ 165 87 82 1.06(0.85,1.31) 47.3 (0.039) 50.6 3.3 (–4.3,10.9)
Number of positive nodes
0 867 147 161 0.91(0.77,1.07) 83.0 (0.013) 84.0 1.0 (−1.5,3.5)
1–3 407 143 120 1.19(1.00,1.40) 64.9 (0.024) 72.1 7.2 (2.5,11.9)
4–9 215 112 93 1.20(0.99,1.45) 47.9 (0.034) 58.2 10.3 (3.6,17.0)
10+ 104 71 62 1.15(0.89,1.44) 31.7 (0.046) 39.9 8.2 (−0.8,17.2)
Unknown 56 15 17 0.88(0.49,1.46) 73.2 (0.059) 73.5 0.3 (−11.3,11.9)
ER status
Negative 637 224 197 1.14(0.99,1.30) 64.8 (0.019) 71.5 6.7 (3.0,10.4)
Positive 816 205 206 1.00(0.86,1.14) 74.9 (0.015) 78.2 3.3 (0.4,6.2)
Unknown 196 59 51 1.16(0.88,1.49) 69.9 (0.033) 76.8 6.9 (0.4,13.4)
PR status
Negative 485 160 153 1.05(0.89,1.22) 67.0 (0.021) 70.7 3.7(−0.4,7.8)
Positive 564 128 136 0.94(0.79,1.12) 77.3 (0.018) 79.9 2.6 (−0.9,6.1)
Unknown 600 200 165 1.21(1.05,1.39) 66.7 (0.019) 74.1 7.4 (3.7,11.1)
Her2 status
Negative 269 72 66 1.09(0.85,1.37) 73.2 (0.027) 78.3 5.1(−0.2,10.4)
Equivocal 13 6 4 1.50(0.55,3.26) 53.8 (0.138) 65.5 11.7 (−15.3,38.7)
Positive 335 113 110 1.03(0.85,1.24) 66.3 (0.026) 69.1 2.8 (−2.3,7.9)
Unknown 1032 297 273 1.09(0.97,1.22) 71.2 (0.014) 76.8 5.6 (2.9,8.3)
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were selected for comparison of observed and predicted
survival. As NUH and TTSH did not collect details of
hormone therapy and chemotherapy regimen data before
2006, therapy calculator was only validated for UMMC
patients with minimum 5-year follow up (N = 1538).
Statistical analysis
Nodal status calculator
Observed and predicted probability of positive lymph nodes
were compared. Calibration was assessed by dividing the
data into deciles based on the predicted probability of posi-
tive nodes and then plotting the observed probability of posi-
tive nodes against means of predicted probability for each
decile. A 45 degree diagonal line was plotted to illustrate per-
fect agreement. Discrimination of nodal status calculator was
evaluated by area under the curve (AUC) in receiver operat-
ing characteristic analysis. A value of 0.5 indicates no dis-
crimination and a value of 1.0 means perfect discrimination.
Outcome and therapy calculator
Ratio of observed and predicted numbers of death
within 5 years and 10 years of diagnosis were calculated
as mortality ratio (MR) with 95 % confidence interval
(CI) constructed by exact procedure [25]. MR was also
calculated for different subgroups by country, period of
diagnosis, age, race, and other clinical characteristics.
Observed 5-year and 10-year survival rates were com-
pared with the median predicted survival from Cancer-
Math. A difference of less than 3 % would be considered
reliable enough for clinical use as 10-year survival bene-
fit of 3–5 % is an indication for adjuvant chemotherapy
[26]. The relationship of average 5-year and 10-year pre-
dicted survival and observed 5-year and 10-year survival
was illustrated by the calibration plot. Discrimination of
outcome and therapy calculator was evaluated by AUC
using dataset with minimum 5-year and 10-year follow-
up accordingly. Outcome calculator was further evalu-
ated using concordance index (c-index) proposed by
Harrell et al. for the entire dataset regardless of follow-
up time [27]. C-index is the probability of correctly dis-
tinguishing patient who survives longer within a random
pair of patients [27]. Like for the AUC, a c-index of 0.5
indicates no discrimination and a c-index of 1.0 means
perfect discrimination.
Conditional survival calculator
For patients who survived two years after diagnosis, pre-
dicted 5-year survival was compared with observed 5-
year survival. Similarly predicted 10-year survival was
compared with observed 10-year survival for patients
who survived 5 years and 7 years respectively. Discrim-
ination was evaluated by AUC.
Results
In total, 7064 female breast cancer patients were included.
Tables 1, 2, 3 and 4 present clinical characteristics of 6807
patients with nodal status, 4517 patients with minimum
5-year follow-up, 1649 patients with 10-year follow-
up, and 1538 patients with detailed treatment data
and minimum of 5-years follow-up, respectively.
Nodal status calculator
A total of 6807 patients with nodal status data were
selected for validation of nodal status calculator. In
this dataset, 43.6 % patients (n = 2970) (95 % CI,
42.5 %–44.8 %) had at least one positive lymph node and
the median predicted probability was 40.6 %. CancerMath
underestimated the probability of positive node for most
of the subgroups (Table 1). The calibration plot (Fig. 1)
also illustrated underestimation except for the last two
deciles. The discrimination of this calculator was fair, with
AUC of 0.71 (95 % CI, 0.70–0.72).
Outcome calculator
The observed number of deaths within 5 years after
diagnosis was significantly higher than the predicted
Table 3 Observed and predicted 10-year overall survival from outcome calculator, stratified by patients’ characteristics (Continued)
Histology
Ductal 1418 445 401 1.11(1.01,1.22) 68.6 (0.012) 74.4 5.8 (3.4,8.2)
Lobular 78 18 21 0.86(0.51,1.35) 76.9 (0.048) 75.7 −1.2 (−10.6,8.2)
Mucinous 59 9 9 1.00(0.46,1.90) 84.7 (0.047) 91.2 6.5 (−2.7,15.7)
Others 91 16 22 0.73(0.42,1.18) 82.4 (0.040) 77.7 −4.7 (−12.5,3.1)
Unknown 3 0 1 - 100 74.4 −25.6
Grade
1 200 22 31 0.71(0.44,1.07) 89.0 (0.022) 89.3 0.3 (−4.0,4.6)
2 668 188 176 1.07(0.92,1.23) 71.9 (0.017) 77.1 5.2 (1.9, 8.5)
3 510 196 172 1.14(0.99,1.31) 61.6 (0.022) 70.0 8.4 (4.1,12.7)
Unknown 271 82 76 1.08(0.86,1.34) 69.7 (0.028) 73.3 3.6 (−1.9,9.1)
Numbers marked in bold indicate statistically significant difference at the 95% confidence level
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(%) (95 % CI)
Overall 1538 286 173 1.65(1.47,1.86) 81.4 (0.010) 89.8 8.4(6.4,10.4)
Ethnicity
Chinese 1052 167 113 1.48(1.26,1.72) 84.1 (0.011) 90.4 6.3(4.1,8.5)
Malay 264 62 30 2.07(1.58,2.65) 76.5 (0.026) 89.4 12.9(7.8,18.0)
Indian 212 54 29 1.86(1.40,2.43) 74.5 (0.030) 87.2 12.7(6.8,18.6)
Other 10 3 1 3.00(0.62,8.77) 70.0 (0.145) 88.2 18.2(−10.2,46.6)
Period of diagnosis
1990–1994 95 39 14 2.79(1.98,3.81) 58.9 (0.05) 86.8 27.9 (18.1,37.7)
1995–1999 374 93 40 2.33(1.88,2.85) 75.1 (0.022) 90.9 15.8 (11.5,20.1)
2000–2003 568 91 63 1.44(1.16,1.77) 84.0 (0.015) 89.7 5.7 (2.8,8.6)
2004–2007 501 63 56 1.13(0.86,1.44) 87.4 (0.015) 90.2 2.8 (−0.1,5.7)
Age at diagnosis
0–39 205 55 17 3.24(2.44,4.21) 73.2 (0.031) 92.6 19.4(13.3,25.5)
40–49 515 74 41 1.80(1.42,2.27) 85.6 (0.015) 92.9 7.3 (4.4,10.2)
50–59 449 86 50 1.72(1.38,2.12) 80.8 (0.019) 89.4 8.6 (4.9,12.3)
60–69 271 43 40 1.08(0.78,1.45) 84.1 (0.022) 86.1 2.0 (−2.3,6.3)
70+ 98 28 24 1.17(0.78,1.69) 71.4 (0.046) 77.4 6.0 (−3.0,15.0)
Tumor size (mm)
0–20 547 51 39 1.31(0.97,1.72) 90.7 (0.012) 94.2 3.5 (1.1,5.9)
21–50 813 170 102 1.67(1.43,1.94) 79.1 (0.014) 88.5 9.4 (6.7,12.1)
51+ 178 65 32 2.03(1.57,2.59) 63.5 (0.036) 82.8 19.3 (12.2,26.4)
Number of positive nodes
0 806 72 70 1.03(0.80,1.30) 91.1 (0.010) 92.4 1.3(−0.7,3.3)
1–3 389 83 46 1.80(1.44,2.24) 78.7 (0.021) 89.4 10.7(6.6,14.8)
4–9 192 64 30 2.13(1.64,2.72) 66.7 (0.034) 85.8 19.1(12.4,25.8)
10+ 123 61 23 2.65(2.03,3.41) 50.4 (0.045) 82.3 31.9(23.1,40.7)
Unknown 28 6 4 1.50(0.55,3.26) 78.6 (0.078) 90.6 12.0 (−3.3,27.3)
ER status
Negative 528 146 73 2.00(1.69,2.35) 72.3 (0.019) 87.2 14.9(11.2,18.6)
Positive 850 99 82 1.21(0.98,1.47) 88.4 (0.011) 91.7 3.3 (1.1,5.5)
Unknown 160 41 18 2.28(1.63,3.09) 74.4 (0.035) 89.8 15.4 (8.5,22.3)
PR status
Negative 423 106 57 1.86(1.52,2.25) 74.9 (0.021) 87.4 12.5(8.4,16.6)
Positive 586 73 58 1.26(0.99,1.58) 87.5 (0.014) 91.6 4.1 (1.4,6.8)
Unknown 529 107 58 1.84(1.51,2.23) 79.8 (0.017) 90.2 10.4 (7.1,13.7)
Her2 status
Negative 665 78 68 1.15(0.91,1.43) 88.3 (0.012) 91.1 2.8 (0.4,5.2)
Equivocal 35 7 4 1.75(0.70,3.61) 80.0 (0.068) 89.9 9.9 (−3.4,23.2)
Positive 418 84 53 1.58(1.26,1.96) 79.9 (0.020) 87.9 8.0 (4.1,11.9)
Unknown 420 117 48 2.44(2.02,2.92) 72.1 (0.022) 89.7 17.6 (13.3,21.9)
Histology
Ductal 1346 270 155 1.74(1.54,1.96) 79.9 (0.011) 89.6 9.7 (7.5,11.9)
Lobular 71 7 7 1.00(0.40,2.06) 90.1 (0.035) 91.0 0.9 (−6.0,7.8)
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number of deaths (752 vs 667, MR = 1.13, 95 % CI 1.05–
1.21). The number of observed and predicted number of
deaths within 10 years after diagnosis was not significant
(488 vs 454, MR = 1.07, 95 % CI 0.98–1.17). The abso-
lute differences of 5-year and 10-year predicted and ob-
served survival probabilities were 3.9 % and 4.9 %.
Overestimation was more pronounced in Malaysian
patients than in Singaporean patients (5.8 % vs 2.5 % for
5-year survival, and 8.0 % vs 0.0 % for 10-year survival).
We also observed notable differences for cases diag-
nosed in earlier period and of younger age (Tables 2 and
3). In addition, CancerMath significantly overpredicted
survival for patients with unfavorable prognostic charac-
teristics such as large tumor size, more positive nodes
and ER negative tumor. For those with relatively better
predicted survival, CancerMath predictions were similar
to observed outcome (Fig. 2a, b and c). The difference
between 5-year predicted and observed survival was
15 %, 3 % and 1 % for the first, fifth, and tenth dec-
iles respectively. The Kaplan-Meier curves of overall
survival by quintiles of predicted 5-year survival were
illustrated in Fig. 3. The difference in survival experi-
ence between the five groups was statistically signifi-
cant (p-value < 0.001 by the log-rank test). The AUC
for 5-year and 10-year overall survival were 0.77
(95 % CI,0.75–0.79) and 0.74 (95 % CI,0.71–0.76), re-
spectively whereas the c-index was 0.74 (95 % CI, 0.72–
0.75). Both measures demonstrated fair discrimination.
Table 4 Observed and predicted 5-year overall survival from therapy calculator, stratified by patients’ characteristics (Continued)
Mucinous 58 1 4 0.25(0.01,1.39) 98.3 (0.017) 96.0 −2.3 (−5.6,1.0)
Others 63 8 7 1.14(0.49,2.25) 88.9 (0.040) 89.7 0.8 (−7.0,8.6)
Grade
1 161 8 11 0.73(0.31,1.43) 95.0 (0.017) 95.6 0.6 (−2.7,3.9)
2 661 111 71 1.56(1.29,1.88) 83.2 (0.015) 90.5 7.3 (4.4,10.2)
3 433 119 59 2.02(1.67,2.41) 72.5 (0.021) 87.7 15.2 (11.1,19.3)
Unknown 283 48 32 1.50(1.11,1.99) 83.0 (0.022) 89.8 6.8 (2.5,11.1)
Chemo-therapy
No chemo-therapy 440 58 53 1.09(0.83,1.41) 86.8 (0.016) 90.4 3.6 (0.5,6.7)
1st Gen 162 49 21 2.33(1.73,3.08) 69.8 (0.036) 88.1 18.3 (11.2,25.4)
2nd Gen 915 174 97 1.79(1.54,2.08) 81.0 (0.013) 90.0 9.0 (6.5,11.5)
3rd Gen 21 5 2 2.50(0.81,5.83) 76.2 (0.093) 90.8 14.6 (−3.6,32.8)
Hormone-therapy
No 398 108 51 2.12(1.74,2.56) 72.9 (0.022) 87.7 14.8 (10.5,19.1)
Yes 1140 178 122 1.46(1.25,1.69) 84.4 (0.011) 90.8 6.4 (4.2,8.6)



































Predicted probability of positive nodes from CancerMath
Fig. 1 Calibration plot of observed probability of positive nodes with 95 % confidence interval against predicted probability of positive nodes
(mean) by deciles of the predicted value
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Therapy calculator
For therapy calculator which was only validated in
Malaysian patients, predicted survival was significantly
higher than the observed survival for almost all sub-
groups, except for those diagnosed recently and with
more favorable tumor characteristics (Table 4, Fig. 2d).
The calculator showed fair discrimination at 5-year over-
all survival (AUC = 0.73, 95 % CI 0.70–0.77).
Conditional survival calculator
For patients who have survived 2 years since diagnosis,
the predicted 5-year survival was 91.0 % versus the ob-
served survival of 88.3 %. The AUC was 0.75 (95 % CI,
0.73–0.77). For patients who have survived 5 years and
7 years, the predicted probability of surviving up to
10 years was 86.6 % and 91.7 %. Whereas the observed
survival was 85.3 % and 91.0 % correspondingly. The
AUC was 0.66 (95 % CI, 0.62–0.70) and 0.63 (95 % CI,
0.57–0.68) for 10-year survival.
Discussion
Many prognostic tools have been developed over the
past two decades to aid clinical decision making for
breast cancer patients. This study validated four different
prognostic calculators provided by CancerMath in the
Singapore-Malaysia Hospital-Based Breast Cancer
Registry. The discrimination was fair for nodal status cal-
culator. CancerMath outcome, therapy and conditional
survival calculator also moderately discriminated between
survivors and non-survivors at 5 years and 10 years after
diagnosis. It however consistently overestimated survival
for this cohort of Southeast Asian patients, especially for
those with poor prognostic profile.
CancerMath was previously built and validated using
SEER data and patients diagnosed at Massachusetts
General and Brigham and Women’s Hospitals [19]. In
the SEER database, 82.7 % of the invasive breast cancer
cases diagnosed between 2003 and 2007 were white and
only 6.9 % were Asian/ /Pacific Islander [28]. It was
shown that the differences between observed and pre-
dicted survival was within 2 % for 97 % of the patients
in the validation set [19]. Our study is the first one to in-
dependently validate CancerMath outside United States
and is also the largest validation study of a western-
derived breast cancer prognostic model in Asia. We
demonstrated that CancerMath overpredicted survival
by more than 3 % for almost all clinical and pathological
subgroups. The findings were similar to previous valid-
ation studies of Adjuvant! Online conducted in Asia. In
the Malaysian, Korean, and Taiwanese studies, the pre-
dicted and observed 10-year overall survival differed by

























































































































Predicted 5-year survival from CancerMath outcome calculator
Fig. 2 Calibration plot of observed survival with 95 % confidence interval against predicted survival (mean) by deciles of the predicted value.
a 5-year survival from outcome calculator for Malaysian patients, b 5-year survival from outcome calculator for Singaporean patients,
c 10-year survival from outcome calculator, d 5-year survival from therapy calculator
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AUC of Adjuvant! Online was 0.73 (95 % CI, 0.69–0.77)
in the Malaysian study and hence very close to the AUC
of CancerMath reported in the present study [16]. Fur-
thermore the prediction was too optimistic for young
patients in almost all validation studies of Adjuvant!
Online [12, 15–17]. Although adjustment of 1.5-fold in-
crease in risk was added to Adjuvant! Online version 7.0
for patients younger than 36 years and with ER positive
breast cancer, overprediction was still found in recent
validation studies [12, 16, 17]. Our findings from current
validation of CancerMath also suggested that correction
for young age at diagnosis is needed.
The selection of patients for validation can partially
explain the discrepancy in observed and predicted sur-
vival. CancerMath has only been validated among pa-
tients with tumor size no more than 50 mm and positive
nodes no more than seven [29]. In our validation data-
set, 10 % of patients had tumor size larger than 50 mm
and 8 % had more than ten positive nodes. However
even for patients with tumor size in between 20 mm and
50 mm and one to three positive nodes, the difference
between the predicted and observed survival was more
than 3 %. In general, Asian patients are more likely to
present with unfavorable prognostic features such as
young age, negative hormone receptor status, HER2
overexpression, and more advanced stage compared to
their western counterparts [30–32]. In our current
analysis, reduced agreement was observed for patients
with poorer predicted outcome, especially for Malaysian
patients, as illustrated by the calibration plot. In
addition, the slope of the calibration plot for Malaysian
patients were greater than 1 for the first three deciles
which suggested that the spread of the predicted survival
was less than observed survival. CancerMath’s poorer per-
formance in Malaysia might be explained by higher pro-
portion of patients in advanced stages and more
heterogeneous prognosis in Malaysia. Such limitation of
CancerMath may restrict its use to patients with better
prognostic profile only. Furthermore CancerMath therapy
calculator applies the same amount of risk reduction from
adjuvant therapy as Adjuvant! Online, which was esti-
mated from meta-analysis of clinical trials mainly con-
ducted in western population [9, 19]. However non-
adherence to treatment is more common among Asian
women [33–35]. Studies also reported different drug me-
tabolism and toxicity induced by chemotherapy between
Asian and Caucasian patients [36]. These evidences may
imply CancerMath overestimate the effect of treatment in
Asian patients.
Another possible explanation of suboptimal perform-
ance of CancerMath and also the limitation of our study
is missing data on ER (6 %), PR (15 %), HER2 status
(47 %), and tumor grade (11 %). For patients with
complete information on required predictors (N = 1872),
Fig. 3 Kaplan-Meier curves of overall survival by quintiles of 5-year predicted survival from outcome calculator
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the predicted and observed 5-year survival was 86.0 %
and 82.5 %. The difference were similar to what we
observed in the entire dataset. Therefore the impact of
missing data is relatively small on performance of
CancerMath.
Several gene expression profiling assays, such as
MammaPrint [37] and Oncotype Dx [38] are currently
available for breast cancer prognostication and treatment
decision. However these tools do not incorporate clinico-
pathologic factors which are readily available or relatively
cheap to obtain. Due to the high cost of these tests and
larger proportion of patients with high predicted risk in
Asia [39, 40], the clinical utility is uncertain in this region.
Therefore traditional prognostic model using clinicopath-
ologic factors seems more reasonable in our local setting.
Conclusions
In conclusion, CancerMath demonstrated modest dis-
crimination and calibration among Southeast Asian
patients. Our results suggest that CancerMath is more
suitable for patients diagnosed with favorable disease.
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